Malaria treatment: Halofantrine

There is still no cure for malaria, which is transmitted by infected mosquitoes. Halofantrine was developed by SRI in 1975.

SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.

Read more from SRI